Biosimilar Switching Studies May Not Be Worth Effort For US Interchangeability, Sponsors Say
Executive Summary
Payers are driving the selection of reference products or biosimilars, creating an ‘artificial interchangeability’ unlikely to be affected by the actual regulatory designation, industry reps say; former FDA commissioner Scott Gottlieb says misinformation campaigns around biosimilar and interchangeable products may lead to enforcement by the FDA and Federal Trade Commission.
You may also be interested in...
How Might FDA Be Convinced To Change Biosimilar Naming Policy?
Following FDA/FTC workshop, several stakeholders urge FDA to do away with suffixes for biosimilar names while others seek reconsideration of switching studies for interchangeability.
Biosimilar Competition: How Might FDA Be Convinced To Change Its Naming Policy?
Following FDA/FTC workshop, several stakeholders urge FDA to do away with suffixes for biosimilar names while others seek reconsideration of switching studies for interchangeability.
Amgen Sees A Vibrant US Biosimilars Market
Biosimilar executives Leah Christl and Chad Pettit see reasons for optimism in the US market as new launches and sales begin to add up. Amgen’s portfolio is annualizing at $1bn as of the fourth quarter.